Aelis Farma announces the recruitment of the first patient in the phase 2b study on AEF0117 in the treatment of the harmful effects of cannabis use, a study which should include approximately 330 patients in nine participating centers in the United States.
This clinical study, conducted double-blind and against placebo, will include four groups of patients, who will be administered either the placebo or one of the three test doses of AEF0117 once a day for three months.
The main objective is to demonstrate whether AEF0117 reduces cannabis consumption, by demonstrating the increase in the proportion of subjects reducing their consumption compared to placebo. The results of the study are expected in 2024.
Copyright (c) 2022 CercleFinance.com. All rights reserved.